Adam Walsh
Stock Analyst at Roth MKM
(3.48)
# 2,239
Out of 4,417 analysts
122
Total ratings
44.6%
Success rate
5.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintained: Buy | $212 | $95.52 | +121.94% | 21 | Jun 8, 2026 | |
| EQ Equillium | Reiterated: Buy | $12 | $2.75 | +336.36% | 8 | Jun 2, 2026 | |
| BIOA BioAge Labs | Initiated Coverage: Buy | $36 | $20.49 | +75.70% | 1 | May 27, 2026 | |
| VTVT vTv Therapeutics | Reiterated: Buy | $58 | $32.28 | +79.68% | 4 | May 13, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $20 | $7.14 | +180.11% | 5 | May 8, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $70 → $82 | $24.85 | n/a | 19 | May 18, 2020 | |
| ASND Ascendis Pharma | Reiterated: Buy | $81 → $171 | $231.20 | n/a | 3 | Apr 20, 2020 | |
| LKFT Lakefront Biotherapeutics NV | Maintained: Buy | $298 | $28.18 | n/a | 9 | Apr 8, 2020 | |
| CORT Corcept Therapeutics | Maintained: Hold | n/a | $83.71 | n/a | 8 | Feb 10, 2020 | |
| KYNB Kyntra Bio | Maintained: Buy | $71 | $6.91 | n/a | 2 | Nov 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $25 | $1.78 | n/a | 4 | Jun 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $11 → $17 | $110.64 | n/a | 3 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $0.6043 | n/a | 3 | Nov 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $129 → $182 | $453.17 | n/a | 13 | Jul 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $107 | $55.12 | n/a | 5 | Mar 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $223.95 | $6.93 | n/a | 1 | Nov 30, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $281.90 | n/a | 11 | Jun 24, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 → $30 | $15.78 | n/a | 2 | May 20, 2015 |
Insmed
Jun 8, 2026
Maintained: Buy
Price Target: $212
Current: $95.52
Upside: +121.94%
Equillium
Jun 2, 2026
Reiterated: Buy
Price Target: $12
Current: $2.75
Upside: +336.36%
BioAge Labs
May 27, 2026
Initiated Coverage: Buy
Price Target: $36
Current: $20.49
Upside: +75.70%
vTv Therapeutics
May 13, 2026
Reiterated: Buy
Price Target: $58
Current: $32.28
Upside: +79.68%
Arcturus Therapeutics Holdings
May 8, 2026
Reiterated: Buy
Price Target: $20
Current: $7.14
Upside: +180.11%
Ultragenyx Pharmaceutical
May 18, 2020
Maintained: Buy
Price Target: $70 → $82
Current: $24.85
Upside: n/a
Ascendis Pharma
Apr 20, 2020
Reiterated: Buy
Price Target: $81 → $171
Current: $231.20
Upside: n/a
Lakefront Biotherapeutics NV
Apr 8, 2020
Maintained: Buy
Price Target: $298
Current: $28.18
Upside: n/a
Corcept Therapeutics
Feb 10, 2020
Maintained: Hold
Price Target: n/a
Current: $83.71
Upside: n/a
Kyntra Bio
Nov 12, 2019
Maintained: Buy
Price Target: $71
Current: $6.91
Upside: n/a
Jun 25, 2019
Maintained: Buy
Price Target: $36 → $25
Current: $1.78
Upside: n/a
May 8, 2019
Upgraded: Buy
Price Target: $11 → $17
Current: $110.64
Upside: n/a
Nov 5, 2018
Maintained: Buy
Price Target: $35
Current: $0.6043
Upside: n/a
Jul 18, 2017
Rated: Buy
Price Target: $129 → $182
Current: $453.17
Upside: n/a
Mar 3, 2016
Reiterated: Buy
Price Target: $105 → $107
Current: $55.12
Upside: n/a
Nov 30, 2015
Initiated Coverage: Buy
Price Target: $223.95
Current: $6.93
Upside: n/a
Jun 24, 2015
Maintained: Buy
Price Target: $160
Current: $281.90
Upside: n/a
May 20, 2015
Upgraded: Buy
Price Target: $16 → $30
Current: $15.78
Upside: n/a